$LUMO
Lumos Pharma Inc Stock $lumo

$lumo Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-K Financial Statement

#000112623415000054 Filed on March 16, 2015

Income Statement

Concept	2013 Q4	2013 Q3	2013 Q2
Revenue	$294.0K	$265.0K	$232.0K
YoY Change	-1.67%	-18.96%	-60.68%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.000M	$2.300M	$2.300M
YoY Change	42.86%	64.29%	4.55%
% of Gross Profit
Research & Development	$5.200M	$6.125M	$5.037M
YoY Change	15.56%	28.16%	6.27%
% of Gross Profit
Depreciation & Amortization	$300.0K	$200.0K	$200.0K
YoY Change	50.0%	0.0%	0.0%
% of Gross Profit
Operating Expenses	$8.200M	$8.382M	$7.301M
YoY Change	24.24%	35.74%	5.95%
Operating Profit	-$7.913M	-$8.117M	-$7.069M
YoY Change	25.74%	38.8%	12.19%
Interest Expense	$0.00	$0.00	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$0.00	-$6.000K	-$8.000K
YoY Change		100.0%	0.0%
Pretax Income	-$7.900M	-$8.123M	-$7.077M
YoY Change	25.4%	37.68%	12.33%
Income Tax	$100.0K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$8.046M	-$8.123M	-$7.077M
YoY Change	27.33%	38.83%	12.17%
Net Earnings / Revenue	-2736.73%	-3065.28%	-3050.43%
Basic Earnings Per Share	-$0.31	-$0.32	-$0.28
Diluted Earnings Per Share	-$0.31	-$0.32	-$0.28
COMMON SHARES
Basic Shares Outstanding	25.71M shares	25.70M shares	25.60M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q4	2013 Q3	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$61.50M	$52.00M	$59.30M
YoY Change	183.41%	83.75%	90.68%
Cash & Equivalents	$61.29M	$51.96M	$59.04M
Short-Term Investments	$200.0K	$0.00	$200.0K
Other Short-Term Assets	$800.0K	$400.0K	$500.0K
YoY Change	-11.11%	300.0%	66.67%
Inventory
Prepaid Expenses	$773.0K	$405.0K	$535.0K
Receivables
Other Receivables
Total Short-Term Assets	$63.97M	$54.15M	$61.07M
YoY Change	173.5%	87.23%	85.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.587M	$6.738M	$5.942M
YoY Change	9.06%	10.69%	-5.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$6.587M	$6.738M	$5.942M
YoY Change	9.06%	10.69%	-5.16%
TOTAL ASSETS
Total Short-Term Assets	$63.97M	$54.15M	$61.07M
Total Long-Term Assets	$6.587M	$6.738M	$5.942M
Total Assets	$70.56M	$60.89M	$67.01M
YoY Change	139.75%	73.92%	71.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$612.0K	$973.0K	$1.076M
YoY Change	-37.04%	37.43%	87.13%
Accrued Expenses	$2.861M	$3.869M	$2.817M
YoY Change	72.45%	81.13%	59.51%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$154.0K	$188.0K	$186.0K
YoY Change	3.36%	27.03%	93.75%
Total Short-Term Liabilities	$3.876M	$5.114M	$4.163M
YoY Change	32.79%	62.35%	59.14%
LONG-TERM LIABILITIES
Long-Term Debt	$1.033M	$1.081M	$1.129M
YoY Change	-12.31%	-84.99%	-83.64%
Other Long-Term Liabilities	$7.300M	$7.300M	$7.400M
YoY Change	-1.35%	421.43%	428.57%
Total Long-Term Liabilities	$8.354M	$8.423M	$8.492M
YoY Change	-2.67%	-2.46%	2.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.876M	$5.114M	$4.163M
Total Long-Term Liabilities	$8.354M	$8.423M	$8.492M
Total Liabilities	$12.23M	$13.54M	$12.66M
YoY Change	6.33%	14.87%	16.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$136.0M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00
YoY Change
Treasury Stock Shares
Shareholders Equity	$58.30M	$47.40M	$54.40M
YoY Change
Total Liabilities & Shareholders Equity	$70.56M	$60.89M	$67.01M
YoY Change	139.75%	73.92%	71.23%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2013 Q2
OPERATING ACTIVITIES
Net Income	-$8.046M	-$8.123M	-$7.077M
YoY Change	27.33%	38.83%	12.17%
Depreciation, Depletion And Amortization	$300.0K	$200.0K	$200.0K
YoY Change	50.0%	0.0%	0.0%
Cash From Operating Activities	-$8.000M	-$6.300M	-$4.900M
YoY Change	19.4%	85.29%	2.08%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	-$1.000M	-$200.0K
YoY Change	-50.0%		-50.0%
Acquisitions
YoY Change
Other Investing Activities	-$300.0K	$300.0K	$500.0K
YoY Change	-125.0%	-115.0%	-70.59%
Cash From Investing Activities	-$300.0K	-$800.0K	$300.0K
YoY Change	-130.0%	-60.0%	-78.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	17.70M	0.000	300.0K
YoY Change	5800.0%	-100.0%	-40.0%
NET CHANGE
Cash From Operating Activities	-8.000M	-6.300M	-4.900M
Cash From Investing Activities	-300.0K	-800.0K	300.0K
Cash From Financing Activities	17.70M	0.000	300.0K
Net Change In Cash	9.400M	-7.100M	-4.300M
YoY Change	-274.07%	47.92%	48.28%
FREE CASH FLOW
Cash From Operating Activities	-$8.000M	-$6.300M	-$4.900M
Capital Expenditures	-$100.0K	-$1.000M	-$200.0K
Free Cash Flow	-$7.900M	-$5.300M	-$4.700M
YoY Change	21.54%	55.88%	6.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014	us-gaap	Operating Expenses OperatingExpenses	55019000	USD
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0001126234
CY2015Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28478570	shares
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q2	dei	Entity Public Float EntityPublicFloat	528615385	USD
CY2014	dei	Entity Registrant Name EntityRegistrantName	NEWLINK GENETICS CORP
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013Q4	nlnk	Cash And Cash Equivalents Excluding Certificates Of Deposit CashAndCashEquivalentsExcludingCertificatesOfDeposit	61291000	USD
CY2014Q4	nlnk	Cash And Cash Equivalents Excluding Certificates Of Deposit CashAndCashEquivalentsExcludingCertificatesOfDeposit	190404000	USD
CY2013Q4	nlnk	Computerequipmentundercapitallease Computerequipmentundercapitallease	54000	USD
CY2014Q4	nlnk	Computerequipmentundercapitallease Computerequipmentundercapitallease	54000	USD
CY2013Q4	nlnk	Contractmanufacturingorganizationequipment Contractmanufacturingorganizationequipment	0	USD
CY2014Q4	nlnk	Contractmanufacturingorganizationequipment Contractmanufacturingorganizationequipment	1023000	USD
CY2014	nlnk	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition In Years EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognitionInYears	3
CY2014	nlnk	Employee Service Sharebased Compensation Nonvested Restricted Stock Awards Total Compensation Cost Notyet Recognized Periodfor Recognition In Years EmployeeServiceSharebasedCompensationNonvestedRestrictedStockAwardsTotalCompensationCostNotyetRecognizedPeriodforRecognitionInYears	3.4
CY2014	nlnk	Expected Dividend Yield ExpectedDividendYield	0.00
CY2014Q4	nlnk	Genentech Potential Milestones GenentechPotentialMilestones	1000000000	USD
CY2014	nlnk	Genentech Revenue Allocatedto Licenseand Manufacturing Technology Transfer GenentechRevenueAllocatedtoLicenseandManufacturingTechnologyTransfer	136200000	USD
CY2014	nlnk	Genentech Upfront Payments GenentechUpfrontPayments	150000000	USD
CY2014	nlnk	Grant Date Fair Valueof Restricted Stock Awards Granted GrantDateFairValueofRestrictedStockAwardsGranted	4700000	USD
CY2014	nlnk	Greater Than10 Stockholder Iso Exercise Price Threshold GreaterThan10StockholderIsoExercisePriceThreshold	1.1
CY2012	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	340000	USD
CY2013	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	-213000	USD
CY2014	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	-316000	USD
CY2014Q4	nlnk	Intrinsic Value Price Per Share Base IntrinsicValuePricePerShareBase	39.75
CY2014Q4	nlnk	Intrinsic Value Unvested IntrinsicValueUnvested	28900000	USD
CY2012	nlnk	Iowa Refundable Research Credit IowaRefundableResearchCredit	283000	USD
CY2013	nlnk	Iowa Refundable Research Credit IowaRefundableResearchCredit	329000	USD
CY2014	nlnk	Iowa Refundable Research Credit IowaRefundableResearchCredit	748000	USD
CY2014	nlnk	Iso Stockholder Ownership Threshold IsoStockholderOwnershipThreshold	0.1
CY2013Q4	nlnk	Lab Equipment LabEquipment	3724000	USD
CY2014Q4	nlnk	Lab Equipment LabEquipment	4110000	USD
CY2013Q4	nlnk	Lab Equipment Under Capital Lease LabEquipmentUnderCapitalLease	489000	USD
CY2014Q4	nlnk	Lab Equipment Under Capital Lease LabEquipmentUnderCapitalLease	489000	USD
CY2013Q4	nlnk	Leasehold Improvements Under Capital Lease LeaseholdImprovementsUnderCapitalLease	27000	USD
CY2014Q4	nlnk	Leasehold Improvements Under Capital Lease LeaseholdImprovementsUnderCapitalLease	27000	USD
CY2012	nlnk	Licensing Payments Under All In Licensing Agreements LicensingPaymentsUnderAllInLicensingAgreements	255000	USD
CY2013	nlnk	Licensing Payments Under All In Licensing Agreements LicensingPaymentsUnderAllInLicensingAgreements	88000	USD
CY2014	nlnk	Licensing Payments Under All In Licensing Agreements LicensingPaymentsUnderAllInLicensingAgreements	3100000	USD
CY2014	nlnk	Merck Revenue Allocatedto License MerckRevenueAllocatedtoLicense	29600000	USD
CY2014	nlnk	Merck Revenue Allocatedto Other Deliverables MerckRevenueAllocatedtoOtherDeliverables	170000	USD
CY2014	nlnk	Merck Upfront Payments MerckUpfrontPayments	30000000	USD
CY2012	nlnk	Reduction Of Ipo Offering Costs ReductionOfIpoOfferingCosts	158000	USD
CY2013	nlnk	Reduction Of Ipo Offering Costs ReductionOfIpoOfferingCosts	0	USD
CY2014	nlnk	Reduction Of Ipo Offering Costs ReductionOfIpoOfferingCosts	0	USD
CY2013Q4	nlnk	Royalty Obligation Payable Noncurrent RoyaltyObligationPayableNoncurrent	6000000	USD
CY2014Q4	nlnk	Royalty Obligation Payable Noncurrent RoyaltyObligationPayableNoncurrent	6000000	USD
CY2012	nlnk	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateMinimum	0
CY2013	nlnk	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateMinimum	0
CY2014	nlnk	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateMinimum	0
CY2014Q4	nlnk	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Vesting Term In Years ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageVestingTermInYears	6.3
CY2014Q4	nlnk	Share Based Compensation Shares Authorized Under Stock Option Plans Exercisable Options Weighted Average Vesting Term In Years ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisableOptionsWeightedAverageVestingTermInYears	5.3
CY2013Q4	nlnk	State Research And Development Credit Receivable StateResearchAndDevelopmentCreditReceivable	329000	USD
CY2014Q4	nlnk	State Research And Development Credit Receivable StateResearchAndDevelopmentCreditReceivable	13000	USD
CY2013	nlnk	Stockissuedunder Atm StockissuedunderATM	17441000	USD
CY2014	nlnk	Stockissuedunder Atm StockissuedunderATM	27572000	USD
CY2014	nlnk	Tenant Improvement Allowance TenantImprovementAllowance	622000	USD
CY2013Q4	nlnk	Total Leasehold Improvements And Equipment TotalLeaseholdImprovementsAndEquipment	10445000	USD
CY2014Q4	nlnk	Total Leasehold Improvements And Equipment TotalLeaseholdImprovementsAndEquipment	12554000	USD
CY2013Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1328000	USD
CY2014Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	3716000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	612000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2412000	USD
CY2013Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	130000	USD
CY2014Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2861000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9367000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3858000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4955000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	194038000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	236838000	USD
CY2014	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	4302000	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3200000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4400000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8600000	USD
CY2013Q4	us-gaap	Assets Assets	70557000	USD
CY2014Q4	us-gaap	Assets Assets	238062000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	63970000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	230463000	USD
CY2012	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	53000	USD
CY2013	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2014	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	409000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	35000	USD
CY2014Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	35000	USD
CY2013Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	570000	USD
CY2014Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	570000	USD
CY2013Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	277000	USD
CY2014Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	186000	USD
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	48000	USD
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	36000	USD
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Due In Rolling Year Two CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo	12000	USD
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	1000	USD
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Net Minimum Payments1 CapitalLeasesFutureMinimumPaymentsNetMinimumPayments1	47000	USD
CY2013Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	293000	USD
CY2014Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	384000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39490000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20250000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61291000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	190404000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-19240000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	41041000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	129113000	USD
CY2013Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	249000	USD
CY2014Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	12393000	USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26573023	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27991242	shares
CY2013Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	266000	USD
CY2014Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	280000	USD
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	130000	USD
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	8503000	USD
CY2012	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2013	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	130000	USD
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	14775000	USD
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	6272000	USD
CY2012	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2013	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2013	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2013Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	1400000	USD
CY2014Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	1300000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	84000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	84000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1321000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1238000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	12966000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1085000	USD
CY2012	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2013	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	295000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	550000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	25168000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7141000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	27000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18556000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	966000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	62000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	20000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	120000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4322000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	120000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	107000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	252000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1748000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5191000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25168000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7114000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	27000	USD
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	788000	USD
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	891000	USD
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1097000	USD
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.12
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2013Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.23
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.86
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.54
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.69
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.12
CY2013Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2013Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.23
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.86
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.05
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.32
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.126
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.350
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.383
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.216
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.00
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.00
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.084
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.000
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.029
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.011
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.000
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.000
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.047
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.000
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.000
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.128
CY2014Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	3000000	USD
CY2014Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	18800000	USD
CY2012	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2013	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2014	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	3700000	USD
CY2012	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
CY2013	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
CY2014	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	4302000	USD
CY2012	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
CY2013	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	54000	USD
CY2014	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
CY2012	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2013	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	130000	USD
CY2014	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	8503000	USD
CY2012	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-2988000	USD
CY2013	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-1494000	USD
CY2014	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-5233000	USD
CY2012	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-38000	USD
CY2013	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2000	USD
CY2014	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7108000	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9521000	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19328000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-23321000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-31050000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	117633000	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	130000	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14775000	USD
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	26443000	USD
CY2013Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	USD
CY2014Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	15604000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-909000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	843000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7898000	USD
CY2012	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	USD
CY2013	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	130000	USD
CY2014	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-15734000	USD
CY2012	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-576000	USD
CY2013	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	84000	USD
CY2014	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	83000	USD
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	14051000	USD
CY2012	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	USD
CY2013	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1132000	USD
CY2014	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	2388000	USD
CY2012	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	498000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-134000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	7560000	USD
CY2013	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3186226	shares
CY2012	us-gaap	Interest Expense Debt InterestExpenseDebt	38000	USD
CY2012	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2012	us-gaap	Investment Income Interest InvestmentIncomeInterest	14000	USD
CY2013	us-gaap	Interest Expense Debt InterestExpenseDebt	33000	USD
CY2014	us-gaap	Interest Expense Debt InterestExpenseDebt	26000	USD
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	12000	USD
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	86000	USD
CY2012	us-gaap	Interest Paid InterestPaid	38000	USD
CY2013	us-gaap	Interest Paid InterestPaid	34000	USD
CY2014	us-gaap	Interest Paid InterestPaid	26000	USD
CY2013Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	5588000	USD
CY2014Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	6022000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	12230000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	34285000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	70557000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	238062000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3876000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25021000	USD
CY2013Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1200000	USD
CY2014Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1100000	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8354000	USD
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9264000	USD
CY2012	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2013	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2014	us-gaap	Licenses Revenue LicensesRevenue	165950000	USD
CY2013Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1033000	USD
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	941000	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	154000	USD
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	157000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1508000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	67000000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	33889000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-277000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-141000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13844000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-20471000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-25818000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	109068000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-23321000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-7934000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-7077000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-8123000	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-8046000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-31180000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-9236000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-9163000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-5598000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	126855000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	102858000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-23259000	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	24946000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	32234000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8042000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7069000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8117000	USD
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-7913000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-31141000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9304000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9127000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13026000	USD
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	149030000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	117573000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3960000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1187000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	387000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	430000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	788000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1136000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	32000	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	707000	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	766000	USD
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1200000	USD
CY2014Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2300000	USD
CY2012	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	-38000	USD
CY2013	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	112000	USD
CY2014	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-62000	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	91000	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	60000	USD
CY2012	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	4000	USD
CY2013	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2014	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	222000	USD
CY2012	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1992000	USD
CY2013	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	249000	USD
CY2014	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	17377000	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1323000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1386000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1700000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2014Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	773000	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8333000	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	158000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	66357000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	27572000	USD
CY2012	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1127000	USD
CY2013	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	858000	USD
CY2014	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	2327000	USD
CY2012	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	456000	USD
CY2013	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2014	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	97000	USD
CY2012	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	50000	USD
CY2013	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2014	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1133000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1399000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6587000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7599000	USD
CY2012	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	122000	USD
CY2013	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	66000	USD
CY2014	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	33000	USD
CY2012	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	107000	USD
CY2013	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	149000	USD
CY2014	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	154000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17838000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22713000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35691000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-135977000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33119000	USD
CY2012	us-gaap	Revenue From Grants RevenueFromGrants	1687000	USD
CY2013	us-gaap	Revenue From Grants RevenueFromGrants	1093000	USD
CY2014	us-gaap	Revenue From Grants RevenueFromGrants	6642000	USD
CY2012	us-gaap	Revenues Revenues	1687000	USD
CY2013Q1	us-gaap	Revenues Revenues	302000	USD
CY2013Q2	us-gaap	Revenues Revenues	232000	USD
CY2013Q3	us-gaap	Revenues Revenues	265000	USD
CY2013Q4	us-gaap	Revenues Revenues	294000	USD
CY2013	us-gaap	Revenues Revenues	1093000	USD
CY2014Q1	us-gaap	Revenues Revenues	334000	USD
CY2014Q2	us-gaap	Revenues Revenues	212000	USD
CY2014Q3	us-gaap	Revenues Revenues	2801000	USD
CY2014Q4	us-gaap	Revenues Revenues	169245000	USD
CY2014	us-gaap	Revenues Revenues	172592000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	3195000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	4365000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	8613000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	24.88
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	1700000	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	204209	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	5000	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	21.38
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.736
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.673
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	23.16
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	0	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	153509	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.00
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	23.63
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	45700	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	1000000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.683
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.630
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.614
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.574
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0205
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0214
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0224
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0098
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0089
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0173
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3678956	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.50
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3600000	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1600000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	8500000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	32674	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	672079	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	860250	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	974555	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.02
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.50
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.80
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	154900000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4486564	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5098311	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.89
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.38
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.64
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.00
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	16.53
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	24.38
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	126000000	USD
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2500000	USD
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3000000	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	7500000	USD
CY2012	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2013	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2014	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	6272000	USD
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	330134	shares
CY2012	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	239000	USD
CY2013	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	416000	USD
CY2014	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	466000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	48916000	USD
CY2012	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3195000	USD
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4365000	USD
CY2014	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	8613000	USD
CY2012	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	887000	USD
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	442000	USD
CY2014	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1861000	USD
CY2014	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	222000	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36773000	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17927000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	58327000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	203777000	USD
CY2014Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	120000	USD
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	222000	USD
CY2012	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	4000	USD
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2000000	USD
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-18100000	USD
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20779450	shares
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25275179	shares
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31025099	shares
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20779450	shares
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25275179	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27838873	shares
CY2014	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, and certificates of deposit. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company’s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high quality securities such as money market funds. </font></div></div>
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001126234-15-000054-index-headers.html	Edgar Link	pending
0001126234-15-000054-index.html	Edgar Link	pending
0001126234-15-000054.txt	Edgar Link	pending
0001126234-15-000054-xbrl.zip	Edgar Link	pending
checkptgraphica04.jpg	Edgar Link	pending
confidentialsymbol.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hamechanisma04.jpg	Edgar Link	pending
image1a03a04.gif	Edgar Link	pending
image2a03a04.jpg	Edgar Link	pending
isurplogoa01a04.jpg	Edgar Link	pending
mercklogo.jpg	Edgar Link	pending
newlogoa04.jpg	Edgar Link	pending
nlnk-201312_chartx49546a04.jpg	Edgar Link	pending
nlnk-20141231.xml	Edgar Link	completed
nlnk-20141231.xsd	Edgar Link	pending
nlnk-20141231x10k.htm	Edgar Link	pending
nlnk-20141231xex10105.htm	Edgar Link	pending
nlnk-20141231xex10106.htm	Edgar Link	pending
nlnk-20141231xex10107.htm	Edgar Link	pending
nlnk-20141231xex10108.htm	Edgar Link	pending
nlnk-20141231xex211.htm	Edgar Link	pending
nlnk-20141231xex231.htm	Edgar Link	pending
nlnk-20141231xex311.htm	Edgar Link	pending
nlnk-20141231xex312.htm	Edgar Link	pending
nlnk-20141231xex321.htm	Edgar Link	pending
nlnk-20141231_cal.xml	Edgar Link	unprocessable
nlnk-20141231_def.xml	Edgar Link	unprocessable
nlnk-20141231_lab.xml	Edgar Link	unprocessable
nlnk-20141231_pre.xml	Edgar Link	unprocessable
pipeline201410k.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUMO
Lumos Pharma Inc Stock $lumo

2013 Q4 Form 10-K Financial Statement

#000112623415000054 Filed on March 16, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO Lumos Pharma Inc Stock $lumo

2013 Q4 Form 10-K Financial Statement

#000112623415000054 Filed on March 16, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO
Lumos Pharma Inc Stock $lumo